Achillion Pharmaceuticals Inc. (NASDAQ:ACHN)’s share price shot up 2.1% during trading on Tuesday . The company traded as high as $8.65 and last traded at $8.61, with a volume of 1,061,061 shares traded. The stock had previously closed at $8.43.

A number of research firms have commented on ACHN. Leerink Swann reaffirmed a “hold” rating on shares of Achillion Pharmaceuticals in a research report on Sunday, June 12th. Zacks Investment Research raised shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.00 price objective for the company in a research report on Thursday, May 5th. Jefferies Group reaffirmed a “hold” rating on shares of Achillion Pharmaceuticals in a research report on Thursday, May 5th. JMP Securities raised shares of Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $13.00 price objective for the company in a research report on Thursday, July 7th. Finally, Chardan Capital began coverage on shares of Achillion Pharmaceuticals in a research report on Thursday, July 14th. They set a “sell” rating and a $4.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. Achillion Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $9.63.

The firm’s market capitalization is $1.18 billion. The stock’s 50 day moving average price is $8.51 and its 200 day moving average price is $8.00.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01. During the same period in the prior year, the firm earned ($0.17) earnings per share. Equities analysts forecast that Achillion Pharmaceuticals Inc. will post ($0.64) EPS for the current year.

Several institutional investors have recently modified their holdings of ACHN. Marshall Wace LLP boosted its position in shares of Achillion Pharmaceuticals by 36.8% in the fourth quarter. Marshall Wace LLP now owns 970,862 shares of the biopharmaceutical company’s stock worth $10,476,000 after buying an additional 261,007 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Achillion Pharmaceuticals by 14.0% in the fourth quarter. Rhumbline Advisers now owns 117,525 shares of the biopharmaceutical company’s stock worth $1,268,000 after buying an additional 14,425 shares in the last quarter. Finally, Swiss National Bank boosted its position in shares of Achillion Pharmaceuticals by 6.8% in the fourth quarter. Swiss National Bank now owns 152,400 shares of the biopharmaceutical company’s stock worth $1,644,000 after buying an additional 9,700 shares in the last quarter.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.